Together, our study represents a significant advancement in the field as we demonstrate a compelling proof-of-concept: the ability to differentiate between distinct lymphoma entities by leveraging BCR repertoire NGS on lymphoma-infiltrated tissues through the application of a trained machine learning model. This evidence concerns the gene BCR and lymphoma.